What’s New

News
FDA Grants Revalesio Fast Track Status for Als Investigational Drug RNS60
Revalesio announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track status for its investigational drug RNS60 as a treatment for amyotrophic lateral sclerosis (ALS), also known...
Read more
News
RNS60 Promotes Myelination of Nanofibers by Oligodendrocytes
Myelin, a membrane consisting of proteins and lipids, forms an insulating cover on neuronal axons that contributes to proper functioning of the nervous system. Specialized cells in the brain called...
Read more